How AI-Native Biopharma Is Redefining Drug Discovery and Competitive Advantage Drug Discovery 2.0
Paper | 2026-7-16
8 minute read
Drug Discovery 2.0 marks a shift from efficiency gains to redesigning the entire drug development model. Advances in AI are transforming how
hypotheses are generated and validated, reshaping R&D processes and organizational capabilities. Competitive advantage is increasingly defined
by platforms and data-driven decision-making.
This paper outlines strategic implications for CxOs in the life sciences industry.
Redefining Competition in Drug Discovery in the Age of AI
AI-native companies are transforming drug discovery from incremental efficiency improvements into a fundamentally new innovation model.
This shift represents not just technological advancement, but a structural change in how competitive advantage is created.
Key Takeaways
• AI is shifting drug discovery from process optimization to full model redesign
• Competitive advantage will be defined by platforms, not individual tools
• AI-native companies are creating new business models across the value chain
Why Drug Discovery Is Reaching Its Limits
For decades, drug discovery has faced structural challenges, including long development timelines, high costs, and low success rates.
These constraints have defined the industry’s innovation model.
How AI Is Changing the Foundation of R&D
AI is accelerating hypothesis generation, molecular design, and data analysis, fundamentally reshaping bottlenecks across the drug development lifecycle.
From Efficiency to Model Redesign
The competitive landscape is shifting from optimizing individual steps to rearchitecting the entire drug discovery model.
The full report explores this transformation in depth, including real-world examples and implications.
The Rise of AI-Native Biopharma Companies
AI-native companies are building platforms where drug discovery capabilities themselves become scalable assets, enabling new business models through partnerships and licensing.
Key Implications for CxOs
• Platforms will determine long-term competitive advantage
• R&D is evolving into a value creation engine
• Ecosystems will replace traditional linear models
Dr. Jianmin Jin (Ph.D in International Economic Law)
Chief Digital Economist Fujitsu Ltd.
Senior Director
Marketing Promotion Office
2020 Fujitsu Ltd., Chief Digital Economist. 1998 Fujitsu Research Institute, Senior Fellow.
Dr. Jin's research mainly focuses on global economic, digital innovation/digital transformation, and Dr. Jin has published books such as ”Towards the Creation of a Japan’s Silicon Valley”(2020), etc.
Understand the Future of Drug Discovery
Explore how AI-native companies are redefining competitive advantage
through platform-based innovation and new R&D models.
Related Information
The Evolution of AI Workforce in Manufacturing
Redesigning Management Foundations that Integrate Growth and Trust
From Digital to Physical: AI as a Working Entity
An Era That Calls for Institutional Reform and the Capacity for Self-Adaptation
This paper examines global models for transforming employment systems in the AI era.
From Humanoid Robotics to Industrial Reality
